Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Taiho Oncology.

Reflective Case-Based Oncology Collective™: Translating Recent Evidence to the Real-World Management of Myelodysplastic Syndromes

Release Date: September 13, 2021
Expiration Date: September 13, 2022

Activity Overview

As knowledge about the pathology of myelodysplastic syndrome (MDS) advances, clinicians gain access to more sophisticated tools for risk stratification and therapeutic intervention. However, these improvements require understanding of an increasingly large and complex array of supportive data and recommendations. This vast amount of information presents a substantial challenge for clinicians and particularly for those practicing in the community setting, where clinicians may see only sporadic cases of MDS.

This online, on-demand activity is derived from the Reflective Case-Based Oncology Collective™, a series of meetings bringing together practicing clinicians with researchers in MDS to collectively consider the ramifications of new treatment approaches. Participants can learn about recent advances in MDS through a series of didactic presentations highlighting the most important clinical trial findings and emerging best practices for disease management based on risk stratification.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation and Taiho Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

The live activity series is directed toward medical oncologists and hematologist/oncologists who treat patients with MDS. Pathologists, fellows, nurses, nurse practitioners, physician assistants, pharmacists, and other health care professionals interested in the treatment or management of MDS are also invited to participate in the online activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the impact of risk stratification on treatment decision-making for patients with MDS.
  • Assess updated results from pivotal trials evaluating current and emerging approaches for treating MDS.
  • Implement strategies to monitor and manage treatment-associated toxicities when caring for patients with MDS.
  • Demonstrate the ability to incorporate risk-adapted and evidence-based approaches that allow for optimized MDS care planning.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Rami Komrokji, MD
Rami Komrokji, MD
Senior Member and Section Head, Leukemia & MDS
Vice Chair, Department of Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
Professor, Medicine and Oncologic Sciences
University of South Florida
Tampa, FL

Disclosures: Consultant: AbbVie, Agios Pharmaceuticals, Bristol Myers Squibb/Celgene, Geron, Jazz Pharmaceuticals, Novartis Pharmaceuticals; Speakers Bureau: AbbVie, Agios Pharmaceuticals, Bristol Myers Squibb/Celgene, Jazz Pharmaceuticals.


Amer Zeidan, MBBS, MHS
Amer Zeidan, MBBS, MHS
Associate Professor of Medicine
Director, Continuing Medical Education
Director, Early Therapeutics Research
Section of Hematology
Department of Internal Medicine
Yale University
New Haven, CT

Disclosures: Grant Research Support: Bristol Myers Squibb, AbbVie, Astex Pharmaceuticals, Pfizer, Boehringer-Ingelheim International GmbH, Cardiff Oncology, Incyte, Takeda Oncology, Novartis Pharmaceuticals, Aprea Therapeutics, Amgen, ADC Therapeutics SA, Otsuka America Pharmaceutical; Consultant: Bristol Myers Squibb, AbbVie, Pfizer, Boehringer-Ingelheim International GmbH, Cardiff Oncology, Incyte, Takeda Oncology, Novartis Pharmaceuticals, Aprea Therapeutics, Amgen, Otsuka America Pharmaceutical, Jazz Pharmaceuticals, Agios, Acceleron Pharma, Astellas Pharma, Daiichi Sankyo Company Ltd, Cardinal Health, Taiho Oncology, Seattle Genetics.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By